Advertisement
CRBU vs RXRX
Which Stock Would AI Choose? Caribou Biosciences (CRBU) vs. Recursion Pharmaceuticals (RXRX) Stock Comparison
Key Takeaways
- CRBU has entered a period of strategic uncertainty after announcing it will discontinue its two clinical CAR-T programs and evaluate strategic alternatives.
- RXRX has seen a recent momentum boost from an expanded data-licensing deal with Tempus AI, though its top-line revenue continues to decline.
- Both companies are clinical-stage biotechnology firms with no approved products, relying heavily on external capital to fund research and development (R&D).
- RXRX holds a materially larger cash balance (roughly $557 million as of its latest quarter) versus CRBU (about $114 million), a key contrast in financial runway.
- Near-term risk profiles differ sharply: CRBU faces pipeline wind-down and restructuring, while RXRX faces heavy cash burn tied to its platform ambitions.
- On observable factors such as trend consistency, catalyst breadth, and balance-sheet stability, RXRX currently presents a comparatively stronger relative position.
Introduction
Investors screening clinical-stage biotechnology names increasingly weigh two very different models: traditional drug-development companies and so-called "TechBio" firms that build artificial-intelligence-driven discovery platforms. This stock comparison examines CRBU (Caribou Biosciences), a CRISPR genome-editing company, against RXRX (Recursion Pharmaceuticals), an AI-native drug-discovery firm. Although both operate in the same broad healthcare sector, their recent market positioning has diverged meaningfully. Growth-oriented traders and long-term healthcare investors may find this comparison useful for understanding relative performance, momentum, and balance-sheet stability in a volatile segment of the market.
CRBU Overview and Recent Performance
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing. Its lead programs were allogeneic CAR-T (chimeric antigen receptor T-cell) therapies: vispa-cel for relapsed or refractory B-cell non-Hodgkin lymphoma and CB-011 for multiple myeloma.
Recent market activity has been sharply negative. In early October 2026, the company announced it would discontinue development of both CAR-T programs, implement substantial workforce reductions, and launch a review of strategic alternatives that could include a merger, acquisition, or sale. Management cited a difficult financing environment for allogeneic CAR-T therapies. The shares fell sharply on the news, and several analysts subsequently downgraded the stock, with price targets cut significantly. As of its latest report, the company held roughly $114 million in cash, cash equivalents, and marketable securities. These developments have placed CRBU in a fundamentally different risk category than many peers.
RXRX Overview and Recent Performance
Recursion Pharmaceuticals is a clinical-stage TechBio company that pairs an AI-native drug-discovery platform, known as the Recursion OS, with automated laboratory operations. Its pipeline spans oncology, rare disease, and neuroscience, and it maintains collaborations with large partners including Roche/Genentech, Sanofi, Bayer, and Merck KGaA.
Recent weeks have brought a mix of signals. The stock rallied after Recursion announced an expanded data-licensing agreement with Tempus AI, a move that reinforced investor interest in its platform story. However, that enthusiasm has been tempered by ongoing fundamentals: second-quarter revenue declined year over year as collaboration revenue from Roche/Genentech fell, and the company continues to post net losses. A recent insider selling filing also weighed on sentiment. On the balance-sheet side, Recursion reported roughly $557 million in cash, cash equivalents, and restricted cash, which management has indicated should fund operations into early 2028. This longer runway supports the company's multiple early-stage clinical catalysts.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively monitor and trade thousands of different tickers across a wide range of markets. Because not every bot suits every market regime, Tickeron curates a dedicated Trending AI Robots section that highlights only the bots best aligned with current market conditions. Each bot has its own trading style, strategy, timeframe, performance record, and universe of tickers, so investors can filter for approaches that match their own objectives and risk tolerance. For traders interested in applying systematic, data-driven methods to names like CRBU and RXRX, exploring the Trending AI Robots page offers a practical way to see which automated strategies are currently leading the market.
Head-to-Head Comparison
The most important contrast between these two names is business-model orientation and near-term stability. CRBU is a traditional clinical-stage drug developer now winding down its pipeline, which introduces restructuring risk and strategic-alternatives uncertainty. RXRX, by contrast, is a platform-driven company whose value proposition depends on converting AI-driven discovery into durable drug programs and partnership milestones.
Financial positioning also diverges. Recursion's roughly $557 million cash balance and runway into early 2028 give it more time to advance clinical catalysts, whereas Caribou's smaller cash position and halted development programs leave it with fewer near-term operating options. On growth drivers, RXRX benefits from multiple collaboration relationships and an expanding early-stage pipeline, while CRBU now has limited internal development catalysts.
Risk factors differ as well. Caribou faces execution risk around any strategic transaction and continued equity-price pressure after heavy downgrades. Recursion faces sustained cash burn, declining collaboration revenue, and dependence on future financing and successful clinical readouts. Sector exposure is similar—both are biotechnology names sensitive to rate expectations and biotech financing conditions—but their market sentiment and momentum have moved in opposite directions in recent trading.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, catalyst breadth, and relative positioning, Tickeron's AI would likely favor RXRX over CRBU in the current environment. Recursion's larger cash runway, active collaboration network, and multiple clinical catalysts provide a comparatively more stable foundation, even amid its own volatility. Caribou's decision to discontinue its core programs and explore strategic alternatives introduces a level of uncertainty that reduces trend consistency and forward catalyst visibility. This assessment is probabilistic rather than definitive: both stocks carry elevated risk, and their relative standing could shift with new clinical data, partnership announcements, or changes in the broader biotech financing environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBU is a Hold and RXRX is a Hold.
Momentum Indicator for CRBU turns negative, indicating new downward trend
CRBU saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 81 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CRBU turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 40 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CRBU entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +3.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBU advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
CRBU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.344) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (11.641) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RXRX's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for RXRX moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 26 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXRX as a result. In 79 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
RXRX moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 206 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 105 of 131 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.169) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| CRBU | RXRX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Stochastic ODDS (%) | N/A | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 89% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Advances ODDS (%) | 15 days ago 80% | 10 days ago 83% |
| Declines ODDS (%) | 6 days ago 88% | 1 day ago 86% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRBU’s FA Score shows that 1 FA rating(s) are green while RXRX’s FA Score has 1 green FA rating(s).
- CRBU’s FA Score: 1 green, 4 red.
- RXRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRBU’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).
- CRBU’s TA Score: 3 bullish, 4 bearish.
- RXRX’s TA Score: 5 bullish, 5 bearish.
Price Growth
CRBU (@Biotechnology) experienced а -58.59% price change this week, while RXRX (@Biotechnology) price change was -17.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.22%. For the same industry, the average monthly price growth was -17.98%, and the average quarterly price growth was -18.86%.
Reported Earning Dates
CRBU is expected to report earnings on Nov 10, 2026.
RXRX is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-7.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CRBU and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRBU has been loosely correlated with AXON. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBU jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To CRBU | 1D Price Change % | ||
|---|---|---|---|---|
| CRBU | 100% | -5.41% | ||
| AXON - CRBU | 50% Loosely correlated | -0.26% | ||
| CRSP - CRBU | 46% Loosely correlated | -2.81% | ||
| RXRX - CRBU | 44% Loosely correlated | -4.36% | ||
| EDIT - CRBU | 44% Loosely correlated | -11.09% | ||
| ABSI - CRBU | 43% Loosely correlated | -5.89% | ||
More | ||||